• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重对超重或肥胖患者日常活动问卷的影响:使用来自OASIS 1试验的数据进行心理测量学评估。

Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.

作者信息

von Huth Smith Lisa, Whalley Diane, Yarr Stuart, Comins Jonathan, Fehnel Sheri E

机构信息

Novo Nordisk A/S, Søborg, Denmark.

Patient-Centered Outcomes Assessment, RTI Health Solutions, Towers Business Park, Manchester, UK.

出版信息

Clin Obes. 2025 Aug;15(4):e70015. doi: 10.1111/cob.70015. Epub 2025 Jun 1.

DOI:10.1111/cob.70015
PMID:40452267
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12289406/
Abstract

The Impact of Weight on Daily Activities Questionnaire (IWDAQ) is a patient-reported outcome measure that uses a novel, adaptive design to assess the limitations in daily activities that are most important to individuals attempting to lose weight. During the first round of completing the IWDAQ, respondents are presented with 18 everyday activities that can be limited by excess weight and asked to choose the three activities they would most like to see improve with weight loss. They are then asked to rate the degree of limitation they experience with these three activities at baseline and at follow-up assessments. Using data from a weight-management clinical trial (OASIS 1, NCT05035095), we evaluated the IWDAQ's measurement properties, determined optimal scoring, and estimated thresholds of meaningful within-patient change. Our analyses demonstrated that the IWDAQ Composite Score offers a reliable and valid personalized measure of limitations in daily activities due to excess weight. The adaptive design of the IWDAQ ensures the patient-centricity of the measure, thereby complementing existing measures of functioning in the context of weight-management clinical trials. Evaluations using data from additional studies would be valuable in extending the psychometric evidence for the IWDAQ.

摘要

体重对日常活动的影响问卷(IWDAQ)是一种患者报告的结局指标,它采用新颖的自适应设计来评估对试图减肥的个体最重要的日常活动中的限制。在第一轮完成IWDAQ时,向受访者展示18项可能因超重而受限的日常活动,并要求他们选择三项最希望随着体重减轻而得到改善的活动。然后要求他们对在基线和随访评估时这三项活动所经历的受限程度进行评分。利用一项体重管理临床试验(OASIS 1,NCT05035095)的数据,我们评估了IWDAQ的测量特性,确定了最佳评分,并估计了患者内部有意义变化的阈值。我们的分析表明,IWDAQ综合评分提供了一种可靠且有效的个性化指标,用于衡量因超重导致的日常活动受限情况。IWDAQ的自适应设计确保了该指标以患者为中心,从而在体重管理临床试验背景下补充了现有的功能指标。使用来自其他研究的数据进行评估,对于扩展IWDAQ的心理测量学证据将是有价值的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7df5/12289406/f7095042e8d1/COB-15-e70015-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7df5/12289406/f7095042e8d1/COB-15-e70015-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7df5/12289406/f7095042e8d1/COB-15-e70015-g001.jpg

相似文献

1
Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.体重对超重或肥胖患者日常活动问卷的影响:使用来自OASIS 1试验的数据进行心理测量学评估。
Clin Obes. 2025 Aug;15(4):e70015. doi: 10.1111/cob.70015. Epub 2025 Jun 1.
2
Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.使用比美吉珠单抗治疗化脓性汗腺炎的III期BE HEARD I和II试验的汇总数据,对化脓性汗腺炎生活质量(HiSQOL©)问卷进行心理测量学验证和解释阈值分析。
Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
Is It Possible to Develop a Patient-reported Experience Measure With Lower Ceiling Effect?是否有可能开发一种天花板效应较低的患者报告体验测量方法?
Clin Orthop Relat Res. 2025 Apr 1;483(4):693-703. doi: 10.1097/CORR.0000000000003262. Epub 2024 Oct 25.
5
Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity.移动健康(m-health)智能手机干预措施用于超重或肥胖的青少年和成年人。
Cochrane Database Syst Rev. 2024 Feb 20;2(2):CD013591. doi: 10.1002/14651858.CD013591.pub2.
6
Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.替尔泊肽与肥胖或超重成人的健康相关生活质量:SURMOUNT-3 三期随机试验结果
Diabetes Obes Metab. 2025 May 14. doi: 10.1111/dom.16463.
7
Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity.改变卫生专业人员行为及护理组织方式的干预措施,以促进超重或肥胖儿童及成人减轻体重。
Cochrane Database Syst Rev. 2017 Nov 30;11(11):CD000984. doi: 10.1002/14651858.CD000984.pub3.
8
A New Measure of Quantified Social Health Is Associated With Levels of Discomfort, Capability, and Mental and General Health Among Patients Seeking Musculoskeletal Specialty Care.一种新的量化社会健康指标与寻求肌肉骨骼专科护理的患者的不适程度、能力以及心理和总体健康水平相关。
Clin Orthop Relat Res. 2025 Apr 1;483(4):647-663. doi: 10.1097/CORR.0000000000003394. Epub 2025 Feb 5.
9
Use of endoanal ultrasound for reducing the risk of complications related to anal sphincter injury after vaginal birth.使用经肛门超声降低阴道分娩后肛门括约肌损伤相关并发症的风险。
Cochrane Database Syst Rev. 2015 Oct 29;2015(10):CD010826. doi: 10.1002/14651858.CD010826.pub2.
10
Sexual Harassment and Prevention Training性骚扰与预防培训

本文引用的文献

1
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.每日口服司美格鲁肽 50mg 治疗超重或肥胖成人(OASIS 1 研究):一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Aug 26;402(10403):705-719. doi: 10.1016/S0140-6736(23)01185-6. Epub 2023 Jun 26.
2
Profile and quality of life of the adult population in good health according to the level of vitality: European NHWS cross sectional analysis.根据活力水平评估健康成年人的特征和生活质量:欧洲 NHWS 横断面分析。
BMC Public Health. 2023 Jun 5;23(1):1061. doi: 10.1186/s12889-023-15754-0.
3
Mental health and quality of life in different obesity phenotypes: a systematic review.
不同肥胖表型中的心理健康与生活质量:一项系统综述
Health Qual Life Outcomes. 2022 Apr 19;20(1):63. doi: 10.1186/s12955-022-01974-2.
4
Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT).体重对生活质量影响量表(IWQOL-Lite-CT)临床试验版的验证性心理计量学评估。
Clin Obes. 2021 Oct;11(5):e12477. doi: 10.1111/cob.12477. Epub 2021 Jul 22.
5
Development of the impact of weight on daily activities questionnaire: A patient-reported outcome measure.体重对日常活动影响问卷的编制:一种患者报告结局测量工具。
Clin Obes. 2020 Dec;10(6):e12387. doi: 10.1111/cob.12387. Epub 2020 Sep 15.
6
Obesity in adults: a clinical practice guideline.成人肥胖:临床实践指南。
CMAJ. 2020 Aug 4;192(31):E875-E891. doi: 10.1503/cmaj.191707.
7
Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.肥胖试验中一种新的生活质量测量方法的验证:体重对生活质量的影响 - 简易临床试验版
Clin Obes. 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. Epub 2019 Apr 16.
8
Assessing test-retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula.评估患者报告结局测量的重测信度使用组内相关系数:选择和记录分析公式的建议。
Qual Life Res. 2019 Apr;28(4):1029-1033. doi: 10.1007/s11136-018-2076-0. Epub 2018 Dec 13.
9
Development of the Weight-Related Sign and Symptom Measure.体重相关体征和症状测量方法的开发。
J Patient Rep Outcomes. 2017;2(1):17. doi: 10.1186/s41687-018-0042-9. Epub 2018 Apr 2.
10
How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods.患者导向湿疹量表的最小重要变化分数应如何解释?使用不同方法进行验证。
Br J Dermatol. 2018 May;178(5):1135-1142. doi: 10.1111/bjd.16367. Epub 2018 Apr 17.